Opportunities and challenges for anti-CD73 cancer therapy

Immunotherapy. 2012 Sep;4(9):861-5. doi: 10.2217/imt.12.83.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5'-Nucleotidase / antagonists & inhibitors*
  • 5'-Nucleotidase / physiology
  • Animals
  • Humans
  • Immunotherapy
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Tumor Microenvironment

Substances

  • 5'-Nucleotidase